Navigation Links
Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
Date:4/9/2009

KALAMAZOO, Mich., April 9 /PRNewswire/ -- Tolera Therapeutics, Inc., was granted orphan drug status by the United States Food and Drug Administration (FDA) for its initial lead candidate, TOL101, for prophylaxis of acute rejection of solid organ transplantation. TOL101 is a biologic protein that is designed to safely and specifically target T cells, components of the immune system that play a key role in the rejection, and ultimate failure, of transplanted organs. Organ transplantation is often the only viable treatment for many end-stage organ diseases.

"We are extremely pleased with this current action by the FDA," commented John J. Puisis, President and CEO of Tolera. "We are mobilized to bring TOL101 to market given the patient's need for safer and more effective immune suppression therapy. Doctors are in need of alternatives to traditional immune suppression approaches, and the current industry pipeline offers few solutions to advance patient care and meet this critical need."

The Orphan Drug Act was enacted to allow the FDA to grant a product special orphan status when it is intended to treat rare diseases or conditions -- those that affect fewer than 200,000 people annually in the United States. This special designation waives governmental filing fees, provides the drug sponsor with tax credits related to development expenses, as well as other support. In addition, orphan drug designation creates the opportunity for the sponsor to apply for orphan drug grant money from the U.S. government to help support clinical trials. As an agent with the potential to aid patients with a severe condition, TOL101 meets the stringent FDA requirements for orphan drug designation. This designation will facilitate TOL101's entry into the clinic, where relatively few new therapies have emerged over the last ten years, and there is a growing need for safer, more targeted therapeutic approaches.

About Tolera Thera
'/>"/>

SOURCE Tolera Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
2. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
3. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
4. Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated
5. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
6. Hepatitis B Foundation and AAPCHO Sponsor Congressional Briefing on Zero Tolerance for Hepatitis B
7. Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
8. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
9. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...., Dec. 1 Expanding its European r...c. of Sarasota has appointed Lake Chemicals and Mi... located near Birmingham, England. ,, Osprey b... the agricultural, waste water, and environmental ... open drain fields, and clean up industrial and ma...
(Date:12/1/2009)...ongruent Software agrees to migrate their Microsof...g clients) to Synergy Business Solutions to mainta...ttle, WA (PRWEB) December 1, 2009 -- Synergy Busin...Microsoft Dynamics SL practice of Congruent Softwa...he move was necessary due to a change in Congruent...
(Date:12/1/2009)...BIN, China, Dec. 1 /PRNewswire-Asia-FirstCall/ -- ...l" or "the Company") (Nasdaq: CSKI ), a leading,f...and producing,over-the-counter drugs in the People... the Company has engaged Guangdong Mediacy Kind Me...serve as its exclusive sales agent for the,Company...
(Date:12/1/2009)... new clinical study presented to the American Soci...ensional (3-D) automated ultrasound follicle measu...tro fertilization (IVF) cycle is effective and mor... the follicles. , Gurnee,...lity Center of Chicago has just completed research...
Breaking Biology Technology:Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 3China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 2China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 3Computerized IVF Follicle Measurements are Faster and Give High Success Rates, Says Research from Chicago Fertility Doctors Richard Sherbahn and Todd Deutch 2Computerized IVF Follicle Measurements are Faster and Give High Success Rates, Says Research from Chicago Fertility Doctors Richard Sherbahn and Todd Deutch 3
...monstrate No Adverse Toxic Effects, ATLANTA, Nov....otechnology company developing medicines for the t..., presented Phase I data last week,during the Reti...thalmology,(AAO) Annual Meeting in Atlanta, GA. Th...Intravitreal POT-4 Therapy for Patients with Neova...
...erQ(TM) Systems During the Term of the ...ovember 10 BSP (Biological,Signal Processing Ltd....at,develops and markets innovative systems for non...rt Disease (IHD), announced that it has signed an,...Co., Ltd to distribute,HyperQ(TM) Stress System in...
...GH to Enhance Clinical Skills,Development, DENVER...nounces a new partnership with the University of S...and education services for USF Health hospital,par...als seeking continuing,medical education. The MSC ...ral Hospital, a major teaching affiliate of USF He...
Other Biology Technology:Potentia Pharmaceuticals' Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial 2Potentia Pharmaceuticals' Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial 3BSP Signs Agreement With CMP Trading for Distribution of HyperQ(TM) Stress System, for Early Detection of Ischemic Heart Disease, in South Korea 2Medical Simulation Corporation Announces Partnership With University of South Florida 2Medical Simulation Corporation Announces Partnership With University of South Florida 3
(Date:11/30/2009)...cientists from The Forsyth Institute, the Universi...adsworth Center, have used state-of-the-art techno...eponema pallidum, the bacterium which causes syphi...the bacteria can now be shown in three dimensions....n and reveals previously unknown features, which m...
(Date:11/30/2009)...se is available in German . , The DFG has a...Research Centres as of 1 January 2010. This decisi...tee in Bonn. The new centres will initially be fun... addition, 20 percent overhead funding for indirec...e centres, research topics range from modern prost...
(Date:11/30/2009)...v. 30, 2009) Scientists and engineers from two of...rgy will come together Dec. 7 with leading academ...pumping blood. , Much like moving oil through a ...dy. Both systems need clean, well-functioning pip...ion, to function efficiently. Both industries also...
Breaking Biology News(10 mins):Scientists gain new understanding of disease-causing bacteria 2DFG approves funding for 17 new collaborative research centers 2DFG approves funding for 17 new collaborative research centers 3DFG approves funding for 17 new collaborative research centers 4DFG approves funding for 17 new collaborative research centers 5DFG approves funding for 17 new collaborative research centers 6DFG approves funding for 17 new collaborative research centers 7DFG approves funding for 17 new collaborative research centers 8DFG approves funding for 17 new collaborative research centers 9Similarities of pumping blood and oil examined 2Similarities of pumping blood and oil examined 3PatientAssistance com Proposes a HOLI Solution to American Healthcare Reform 50376 1PatientAssistance com Proposes a HOLI Solution to American Healthcare Reform 50376 2PatientAssistance com Proposes a HOLI Solution to American Healthcare Reform 50376 3Medifast Inc Added to the Russell 3000 Index 50375 1Medifast Inc Added to the Russell 3000 Index 50375 2Medifast Inc Added to the Russell 3000 Index 50375 3Focused Health Solutions Partners With Emmi Solutions to Help Employers Achieve Greater Returns on Their Employee Health Care Investments 50372 1Focused Health Solutions Partners With Emmi Solutions to Help Employers Achieve Greater Returns on Their Employee Health Care Investments 50372 2Focused Health Solutions Partners With Emmi Solutions to Help Employers Achieve Greater Returns on Their Employee Health Care Investments 50372 3
...e in all shapes and sizes, from grand Redwood tree...hem, under the ground plants rely on a complex net... growth has been a mystery, but a new paper publis...pe of the existing root can determine how further ...mone concentration. The work also suggests that th...
...led warming over the last few decades has triggere...orth American and Western European lakes, say rese...stry of the Environment. , The team reports that ...te lakes similar to those previously observed in t... decades later. The Arctic has long been considere...
...ecember 22, 2008 - Shakespeare wrote "a rose by an...f the molecules that generate its,fragrance were t..., Assistant Professor of Chemistry at The City,Col...aboratory of Dr. Stuart,Firestein, Professor of Bi...te. Their findings, reported today in the journal ...
Other Biology News:Study links ecosystem changes in temperate lakes to climate warming 2Shape changes in aroma-producing molecules determine the fragrances we detect 2
Polyvalent HRP AEC Detection System from Spring Bioscience
Total Protein Western Blots - Plant Normal Tissue, Blot I from BioChain
GIBCO Water Distilled Sterile from Invitrogen
Yeast Deletion Parental Strains S. cerevisiae Hansen BY4741 from Invitrogen
Biology Products: